Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | DGAT1 | O75907 | 12/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18134645 | 0.89 | NPSR1 (0.57) | NPSR1MAPK1DGAT1NPC1RAB9A | |
| SCHEMBL22324675 | 0.89 | DGAT1 (0.55) | NPSR1MAPK1DGAT1NPC1RAB9A | |
| SCHEMBL4300650 | 0.89 | NPSR1 (0.59) | NPSR1MAPK1DGAT1NPC1RAB9A | |
| SCHEMBL408901 | 0.89 | NPC1 (0.60) | NPSR1MAPK1DGAT1NPC1RAB9A | |
| SCHEMBL24303811 | 0.88 | CA12 (0.56) | NPSR1MAPK1DGAT1NPC1RAB9A | |
| SCHEMBL408365 | 0.88 | DGAT1 (0.59) | NPSR1MAPK1DGAT1NPC1RAB9A | |
| SCHEMBL16691194 | 0.87 | DGAT1 (0.55) | NPSR1MAPK1DGAT1NPC1ALDH1A1 | |
| SCHEMBL443532 | 0.87 | DGAT1 (0.52) | NPSR1MAPK1DGAT1NPC1RAB9A | |
| SCHEMBL4298281 | 0.87 | DGAT1 (0.66) | NPSR1MAPK1DGAT1NPC1RAB9A | |
| SCHEMBL4299394 | 0.87 | DGAT1 (0.61) | NPSR1MAPK1DGAT1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3087058-B1 | PROCESS FOR THE REGIOSELECTIVE SYNTHESIS OF PYRAZOLES | ISAGRO SPA (IT) | 2017-09-06 | — | — | EP | disclosed |
| US-9676726-B2 | Process for the regioselective synthesis of pyrazoles | ISAGRO S.P.A. (IT) | 2017-06-13 | — | — | US | disclosed |
| US-20160318874-A1 | PROCESS FOR THE REGIOSELECTIVE SYNTHESIS OF PYRAZOLES | FMC IP TECHNOLOGY GMBH (CH) | 2016-11-03 | — | — | US | disclosed |
| EP-3087058-A1 | PROCESS FOR THE REGIOSELECTIVE SYNTHESIS OF PYRAZOLES | ISAGRO S.p.A. (IT) | 2016-11-02 | — | — | EP | disclosed |
| WO-2015097658-A1 | PROCESS FOR THE REGIOSELECTIVE SYNTHESIS OF PYRAZOLES | ISAGRO S.P.A. (IT) | 2015-07-02 | — | — | WO | disclosed |
| EP-1963313-B1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | MADRIGAL PHARMACEUTICALS INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-8211914-B2 | Inhibitors of diacylglycerol acyltransferase | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8153644-B2 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
| EP-2044055-A2 | AMIDE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008141976-A1 | DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | VIA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| EP-1963313-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE (DGAT) | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008011131-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011131-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007060140-A2 | INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE (DGAT) | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-31 | — | — | WO | disclosed |
| US-20070123504-A1 | Diacylglycerol acyltransferase inhibitors | MADRIGAL PHARMACEUTICALS, INC. | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093497-A1 | Diacylglycerol Acyltransferase Inhibitors | DGAT2, DGAT1, LCAT | NPSR1 3148/4885MAPK1 1790/4885DGAT1 2/4885 |
| US-20160318874-A1 | PROCESS FOR THE REGIOSELECTIVE SYNTHESIS OF PYRAZOLES | CYP4F11, CYP2F1, CYP3A4 | NPSR1 2503/4885MAPK1 1228/4885DGAT1 3565/4885 |
| US-20070123504-A1 | Diacylglycerol acyltransferase inhibitors | DGAT2, DGAT1, LCAT | NPSR1 3148/4885MAPK1 1790/4885DGAT1 2/4885 |
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | NPSR1 2899/4885MAPK1 2805/4885DGAT1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.